Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Erlotinib

Erlotinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Erlotinib

212 trials tracked of Erlotinib: 30 in phase 3 or 4 and 6 with published results. The most-cited published study has 5556 citations.

212Trials tracked
30Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 24 Phase 2 165 Phase 1 9 Other / NA 8
  1. Phase 3 Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR Completed · 5,556 cited
  2. Phase 3 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Completed · 165 cited
  3. Phase 3 Erlotinib Prevention of Oral Cancer (EPOC) Completed · 153 cited
  4. Phase 3 A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Completed · 46 cited
  5. Phase 4 An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed · 34 cited
  6. Phase 3 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Completed · 13 cited
Show 44 more trials
  1. Phase 4 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed
  2. Phase 4 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer Completed
  3. Phase 4 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed
  4. Phase 4 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed
  5. Phase 4 Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population Completed
  6. Phase 3 A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Completed
  7. Phase 3 An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study Completed
  8. Phase 3 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed
  9. Phase 3 Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  10. Phase 3 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  11. Phase 3 LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy Completed
  12. Phase 3 A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS) Completed
  13. Phase 3 A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash. Completed
  14. Phase 3 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Completed
  15. Phase 3 A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) Completed
  16. Phase 3 A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors Completed
  17. Phase 3 A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC) Completed
  18. Phase 3 A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone Completed
  19. Phase 3 A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) Completed
  20. Phase 3 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma Completed
  21. Phase 3 A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy Completed
  22. Phase 3 A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Completed
  23. Phase 3 A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer Completed
  24. Phase 3 A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations Completed
  25. Phase 2 A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone Completed
  26. Phase 2 Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma Completed
  27. Phase 2 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Completed
  28. Phase 2 Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer Completed
  29. Phase 2 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer Completed
  30. Phase 2 Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  31. Phase 2 Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed
  32. Phase 2 Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  33. Phase 2 Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer Completed
  34. Phase 2 Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR Completed
  35. Phase 2 A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer Completed
  36. Phase 2 Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia Completed
  37. Phase 2 Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer Completed
  38. Phase 2 Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer Completed
  39. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  40. Phase 2 Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Completed
  41. Phase 2 A Study of Management of Tarceva - Induced Rash in Patients With Non-Small Cell Lung Cancer. Completed
  42. Phase 2 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia Completed
  43. Phase 2 A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations Completed
  44. Phase 2 BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Completed

Showing the 50 most-cited and recently-updated of 212 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer
Allergy & Immunology Sys. Review
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer mRNA Vaccines Show Promise for Lung Cancer Treatment
This systematic review examines the current status and prospects of mRNA vaccines for lung cancer. The authors synthesize evidence that mRNA…
New research explores how mRNA technology can reshape the tumor environment and trigger immune responses to fight lung cancer.
Frontiers Aug 26, 2026
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients
Oncology RCT
CXRT improves survival and disease-free rates specifically in node-negative pancreatic head adenocarcinoma patients Radiotherapy shows promise for specific pancreatic cancer patients
This Phase III multicenter randomized controlled trial of 354 patients with adenocarcinoma of the pancreatic head found no significant diffe…
Adding radiation to chemotherapy may improve survival and stay disease-free for certain patients with pancreatic head cancer.
Aug 22, 2026